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Clinical Relevancy Statement 26 
Patients undergoing hemodialysis induces an imbalance between muscle protein synthesis 27 
and breakdown, leading to loss of muscle mass and function. This study found that short-term 28 
creatine supplementation attenuates the malnutrition-inflammation score and the lean body 29 























   
Abstract 51 
Background: Creatine supplementation has been proposed to alleviate muscle loss in various 52 
populations, but has not been investigated in hemodialysis (HD) patients. Thus, our objective 53 
was to evaluate whether creatine supplementation could attenuate the loss of lean body mass 54 
(LBM) and malnutrition-inflammation score (MIS) in HD patients. Methods: A randomized, 55 
placebo-controlled, double blind, parallel-design study included HD patients, of both sexes, 56 
aged 18-59 years. The patients were allocated to a Placebo Group (PG n=15; received 57 
maltodextrin, 1st week: 40g/day and 2nd-4th weeks: 10g/day) and a Creatine Group (CG n=15; 58 
received creatine plus maltodextrin, 1st week: 20g/day of creatine plus 20g/day of 59 
maltodextrin and 2nd-4th weeks: 5g/day of creatine plus 5g/day of maltodextrin).Pre and post 60 
the intervention, patients were evaluated for food intake, MIS, body composition and 61 
biochemical parameters. Results: CG group attenuated the MIS (Pre:5.57±0.72 vs. 62 
Post:3.85±0.47 score, p=0.003) compared with PG (Pre:5.71±0.97 vs. Post:5.36±0.95 score, 63 
p=0.317) (supplement x time p=0.017, effect size:0.964). The change of LBM was greater in 64 
CG than in PG (CG: Δ 0.95 vs PG: Δ0.13 kg). At post-intervention, 28.6% of PG patients 65 
presented LBM loss and 71.4% remain stable. In contrast, 14.4 % of CG patients had LBM 66 
loss, 42.8% remain stable and 42.8% gained. Food intake and quality of life did not change. 67 
CG increased the BMI and gait speed in post- compared to pre-moment, but no difference 68 
among the groups. Conclusion: In HD patients, four weeks of creatine supplementation may 69 
alleviate the MIS as well as attenuate the LBM loss compared to placebo. 70 







   
Background 76 
The malnutrition-inflammatory score (MIS) is commonly associated with morbidity 77 
and mortality in chronic kidney disease (CKD) patients undergoing hemodialysis (HD)[1] 78 
and non-dialyzed patients [2]. Additionally, a Brazilian study revealed that the MIS is a 79 
useful tool to evaluate the protein-energy wasting (PEW) in CKD patients [2]. Considering 80 
that PEW is a condition of reduced body protein and energy stores [3]and that reduced lean 81 
body mass (LBM) is negatively associated with MIS [4], a new therapeutic strategy to 82 
attenuate LBM loss and MIS values may improve the clinical outcome and the quality of life 83 
(QoL) of HD patients. 84 
Creatine supplementation has been proposed to alleviate muscle loss in various 85 
populations [5]. Kley et al. [6]in a meta-analysis found that creatine supplementation in 86 
patients with muscular my opathies was well tolerated and may lead to an increase in muscle 87 
strength and LBM. However, the impact of creatine supplementation on LBM, MIS and QoL 88 
has not been investigated in HD patients. 89 
 Creatine supplementation may enhance muscular phosphor creatine stores and 90 
stimulate rapid recovery of adenosine triphosphate levels [7, 8]. In addition, water retention 91 
due to Cr-induced reduction in ionic strength may contribute to the gain of body weight, 92 
LBM and muscle strength [9]. Considering that creatine supplementation is safe, inexpensive 93 
and appears to positively modulate body composition in wasting and dialysis patients [8, 10, 94 
11], we hypothesized that four weeks of creatine monohydrate supplementation would lower 95 
the MIS and the LBM loss in HD patients. Thus, our objective was to evaluate whether 96 
creatine supplementation could attenuate the loss of LBM and MIS in CKD patients 97 
undergoing HD.  98 
  99 
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Materials and Methods 100 
Design of study 101 
This randomized, placebo controlled and double blind clinical trial was conducted 102 
with patients of both sexes diagnosed with CKD undergoing HD, aged between 18 and 59 103 
years. The overall study lasted six weeks, and the intervention with creatine was four weeks. 104 
After inclusion of the patients in the study, they were randomly allocated by gender, 105 
age and LBM content. The patients signed the Informed Consent Form approved by the 106 
Research Ethics Committee of the Federal University of Goiás, number 1.470.351 and this 107 
study is part of a larger trial looking at various interventions that was previous registered in 108 
the Brazilian Registry of Clinical Trials under the code RBR-98wzgn. 109 
 110 
Recruitment and sample selection 111 
The sample and criteria of inclusion was composed of patients diagnosed with CKD 112 
undergoing HD treatment for more than three months at the two hemodialysis out patients’ 113 
clinics in Goiânia, GO, Brazil. The Gpower® 3.1 software was used to calculate the sample 114 
size [12], in which a significance level of 5% with statistical power of 80%, effect size 0.50, 115 
two groups and two measurements (LBM and MIS) was considered, so the study population 116 
should be12 patients per group. 117 
Exclusion criteria included patients presenting with neurological disease, severe 118 
cardiovascular diseases, physical disability (amputations, deep vein thrombosis), and patients 119 
who underwent structured physical training three months prior to the date of inclusion in the 120 






   
Experimental groups 125 
The study was performed with 30 patients divided into two groups randomized by 126 
gender, age and LBM content (Supplementary Figure 1): 1) Placebo Group (PG): 127 
Composed of 15 patients which received maltodextrin, and 2) Creatine Group (CG): 128 
Composed of 15 patients which received creatine monohydrate. During the intervention 129 
period, one patient in each group was excluded because of non-adherence to the creatine 130 
supplementation (90% of the recommended dose was accepted as the limit of adhesion). 131 
The intervention was separated into 3 steps after the randomization and division of 132 
the groups (Figure 1): 1)during the 1st week of the study, the initial evaluations were 133 
performed including food intake assessment; MIS (see below for details); blood tests; 134 
anthropometric and body composition (dual energy X-ray absorptiometry); 2) from the 2nd to 135 
the 5th week, the intervention with the creatine and the placebo (see below); and 3) during the 136 
6th week of the study, the same parameters were reassessed within 48 hours after the last 137 
intake of the creatine and the placebo. 138 
 139 
Protocol supplementation 140 
The blinded intervention was performed as described in Table 1. The sachets 141 
containing either creatine or placebo were standardized in order to avoid any identification of 142 
the content by the patients. Creatine loading phase induces an increase rapid intramuscular 143 
creatine phosphate, which allows a small intervention period (MCKENNA et al., 2017)[U1]. 144 
[M2]Because creatine powder had no taste, whereas maltodextrin had lemon flavor, all doses 145 
of creatine contained maltodextrin. Fortunately, the addition of maltodextrin to creatine 146 
favours absorption by the gastrointestinal tract and the uptake by muscle tissue[13]. Both 147 
creatine and maltodextrin were donated by Maxtitanium®, Supley Laboratório de Alimentos 148 
e Suplementos Nutricionais, Matão, SP, Brazil. 149 
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 151 
Evaluation of food intake 152 
Food intake assessments (24h food recall) were conducted by trained nutritionists at 153 
the beginning of the intervention (1st week), during the intervention (3rd week), and at the end 154 
of the intervention (last week).The data were calculated in the Dietpro® software (5.8 155 
version, Agromídia Softwares, Viçosa, MG, Brazil), and the macro and micronutrients 156 
consumption of the patients were quantified. 157 
 158 
Malnutrition-inflammation score (MIS) 159 
MIS is an tool based on Subjective Global Assessment (SGA), which includes three 160 
other items, body mass index (BMI), serum albumin concentrations and total iron binding 161 
capacity (TIBC) [1, 14, 15]. MIS presents clinical history, physical and biochemical analysis 162 
of the patient. The clinical history consists of addressing aspects such as weight reduction in 163 
the last six months, changes in dietary intake, presence of gastrointestinal symptoms and 164 
functional capacity related to nutritional status. Physical examination includes aspects such as 165 
subcutaneous fat loss, muscle loss, the presence of edema resulting from malnutrition and 166 
ascites which have been defined as normal, mild, moderate or severe. And biochemical 167 
parameters, the albumin and TIBC exams. After completed the clinical, physical and 168 
biochemical examinations, the results can range from 1 to 30 and then the classification of the 169 
nutritional status was performed. The score ≤ 6 presents normality and score> 6 presents 170 
classification for malnutrition and high MIS [1, 14, 15]. 171 
 172 
Anthropometric and body composition assessment 173 
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Anthropometric data were collected in the intermediate session of the week of HD 174 
(2nd session). Weight and height were evaluated by an anthropometric digital scale 175 
(Filizola®) for later calculation of BMI. In addition, arm, calf and thigh circumferences were 176 
measured using a flexible tape measure. The data were collected in duplicate by Nutritionists 177 
trained. 178 
The body composition was assessed by dual energy X-ray absorptiometry (DXA) 179 
(Lunar DPX NT, GE Medical Systems Lunar®, Madison, USA). In this equipment collected 180 
the total fat mass and LBM. This method was chosen because muscle mass is correlated with 181 
body size, so to quantify muscle mass, the absolute level of Skeletal Muscle Mass can be 182 
adjusted for body size in different ways. Other method, such as bioimpedance only estimates 183 
the body composition from studies that performed in DXA (CRUZ-JENTOFT et al., 184 
2019)[M3][U4] 185 
Quality of life 186 
QoL was assessed by Short Form 36 (SF-36) which is a well-documented health-187 
related instrument consisting of 36 questions and divided into eight dimensions: physical 188 
functioning, physical role functioning, pain, general health, vitality, social role functioning, 189 
emotional role functioning, mental health. The data of this from vary from 0 to 100 (worse to 190 
best status) and have been validated in a Brazilian population [16]. 191 
 192 
Biochemical analysis 193 
The monthly biochemical analysis performed by the clinics (pre and post serum 194 
urea, phosphorus, albumin and TIBC) were collected in the patients' medical records before 195 
and after the intervention. For the exams not performed periodically, the serum was collected 196 
by nursing and stored at -80C for subsequent quantification of serum creatinine by the 197 
chemiluminescence method in the Roche® Architect 8000 equipment. 198 
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Statistical analysis 200 
The data was deposited in Microsoft Excel® and transcribed into the programs 201 
Statistical Package of Social Sciences (SPSS) 18.0versionand e R Studio 3.4.3 version. 202 
Descriptive statistics (absolute and relative frequencies and standard error of the mean, SEM) 203 
were used. The continuous variables were tested for normality by the Shapiro-Wilk Test. Chi-204 
square test was used to evaluate categorical variables. Differences in food intake and delta of 205 
variables among the PG and CG were tested by Wilcoxon test or Mann-Whitney and Student 206 
t test, respectively. To evaluate the interaction between supplements and intervention time, 207 
two-way ANOVA test followed post hoc of the Tukey was used. The level of statistical 208 
significance was set at 5% (p <0.05). 209 
 210 
Results 211 
Baseline characteristics and food intake 212 
The baseline characteristics of the patients are shown in Table 1.Both groups were 213 
similar for sex, age, BMI and previous comorbidities (Table 2), and food intake (Table 3). 214 
 215 
Malnutrition-inflammation score (MIS) 216 
The MIS showed a significant reduction in CG (Δ: -1.71) compared to PG (Δ: -0.36) 217 
(p= 0.01, with high effect size) (Table 4). 218 
 219 
Anthropometry and body composition 220 
Although no difference among the groups was observed (p= 0.43), both enhanced 221 
the body weight (PG Δ: 0.51 kg vs. CG Δ: 0.77 kg) and the BMI in post compared to pre 222 
moment. In addition, no change in arm, thigh and calf circumferences was found between the 223 
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groups (p>0.05) (Table 4). In contrast, the gait speed was higher in the CG (Δ: 0.05 m/sec) 224 
than PG (Δ: -0.03 m/sec), with high effect size, but no difference among the groups. 225 
LBM was higher in CG (Δ: 0.95 kg) than in (Δ: 0.13 kg) (ANOVA supplement x 226 
time p= 0.03 and high effect size) and higher fat body mass in PG (Δ: 0.39 kg) than in CG (Δ: 227 
-0.17) (ANOVA supplement x time p= 0.02 and high effect size) (Table 4). Additionally, 228 
28.6% and 71.4% of patients of PG presented in end of intervention a LBM loss and remain 229 
stable, respectively (Figure 2A). In contrast, in the CG 14.4% of patients LBM loss, 42.8% 230 
remain stable and 42.8% gained (Figure 2B). Moreover, CG presented in the end of study a 231 
reduction of delta mean fat body mass (p = 0.011, Figure 3A) and increase of delta mean 232 
LBM (p = 0.011, Figure 3B). 233 
 234 
Biochemical analysis 235 
Although the serum creatinine concentrations were increased in CG (Δ: 1.90 mg/dL) 236 
compared to PG (Δ: -0.82 mg/dL) (ANOVA supplement x time p= 0.001 and high effect 237 
size), serum urea pre- and post-hemodialysis concentrations and phosphorus did not alter 238 
with the treatment (p> 0.05) (Table 4). 239 
 240 
Quality of life 241 
QoL did not change in any of the eight domains assessed (Supplementary Table 1). 242 
 243 
Discussion 244 
The present study is the first to investigate the effects of 4 weeks of creatine 245 
supplementation in patients undergoing HD. We showed that supplementation was able to 246 
alleviate the MIS and LBM loss. In addition, 43% of the CG patients gained LBM where no 247 
gain was seen in patients administered the placebo. These results corroborate with the meta-248 
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analysis of Candow et al. 2014 [17], who suggests that creatine supplementation may lead to 249 
physiological benefits and improved body composition across various populations. 250 
Regarding MIS, there was a significant reduction in CG after the intervention. Of 251 
note, three patients previously classified as malnourished improved to normal values. MIS is 252 
an important predictor of mortality among CKD patients on HD [15]. Likewise, a Brazilian 253 
observational retrospective cohort study conducted with 171 patients revealed that the 254 
instrument has 53% sensitivity and 82% specificity for mortality in patients with more than 255 
24 months on HD treatment. Thus, we can observe the importance of reducing the number of 256 
previously malnourished patients, and we can infer that the reduction in the score in the group 257 
supplemented with creatine likely decreases the chances of death [18]. 258 
In the CG, there was a significant increase in body weight, BMI, gait speed and 259 
LBM. These findings corroborate with Johnston et al. 2008 study, who observed that when 260 
immobilizing the arm of healthy young and supplementing them with creatine, there was a 261 
preservation of lean arm mass (+ 0.9%) observed by DXA whereas in the placebo group there 262 
was a reduction (-3.7%) [19]. Likewise, previous studies showed that creatine 263 
supplementation leads to enhanced LBM as well as body weight in young and older adults 264 
[20, 21]. Similar to our study, Gotshalk et al 2008 [22] showed in older adults and elderly 265 
patients that 7 days of creatine supplementation was able to increase body mass and LBM, 266 
(likely, in part due to water retention) as well as to improve the time in gait test. Thus, these 267 
data reinforce the initial hypothesis that short-term creatine supplementation can raise the 268 
LBM and improve muscle function in older people [21] and also in adults with chronic 269 
disease, as observed in the present study. 270 
Regarding biochemical analyses, there was a significant increase in serum creatinine 271 
concentrations in CG when compared to PG. The elevated serum creatinine levels are related 272 
to the fact that approximately 2% of daily creatine is converted into the cyclic degradation 273 
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product and can leave the cells through the permeable cell membrane and enter the 274 
bloodstream without provoking toxic effects on the body[11]. Additionally, low serum 275 
creatinine concentrations (<10[6-10] md/dL), which is a good marker of nutritional status in 276 
HD patients is associated with increased mortality and reduced muscle mass [23, 24], thus we 277 
should study how poor dietary consumption impairs the loss of LBM. 278 
According to Wallimann et al. 2017 [11], intradialytic creatine supplementation is 279 
safe and may improve the QoL of HD patients; however, in the present study, we did not 280 
observe alteration in any domains of SF-36 questionnaire. We believe the present study may 281 
encourage further research with creatine supplementation in CKD patients on HD, as we 282 
observed that creatine generated clinically relevant results, with good compliance by the 283 
patients, with no complaints of ingestion difficulties or side effects.  284 
The present study presented positive points: 1) the use of DXA to evaluate the body 285 
composition, once it allows greater veracity in the results; 2) food intake and protein intake 286 
assessment, since we can affirm that attenuation of LBM and MIS loss were independent of 287 
food consumption, once no changes from the beginning to the end of the study were found. 288 
The main limitationof the study is: 1) we did not evaluate the hydration status which may 289 
have altered the mount of measured LBM that could be accounted for by the accumulation of 290 
intra-muscular water; 2) no physical activity test was applied. 291 
 292 
Conclusion 293 
In HD patients, four weeks of creatine supplementation may alleviate the MIS as well 294 
as attenuate the LBM loss compared to placebo. However, more studies are needed in the 295 
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Figure 1.Study design. 386 
1ª stage: Evaluations (1ªwk); 2ª stage: Intervention (2ª to 5ª wk) and 3ª stage: Revaluations 387 
(6ª wk). 388 
LBM: lean body mass; MIS: malnutrition-inflammation score. 389 
  390 
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 391 
 392 
Figure 2.Delta of individual change in lean body mass (%).  393 
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 394 
Figure 3.Delta of % change in body fat mass (A) and in lean body mass (B) measured by 395 
dual X-ray absorptiometry in the treated and control groups.  396 
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Table 1.Blindedinterventionprotocol. 397 
Groups 
1st week (loading phase) 2-4th week 
four times in day* total in day only one time in day# total in day 
Placebo 
(maltodextrin) 
10g 40g 10g 10g 
Creatine 













*Breakfast, lunch, snack and dinner; #Lunch or dinner; Maltodextrin with lemon flavor.  398 
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Table2. Baseline characteristics. 399 
Variables 
Placebo (n=14) 




Sex (n)#    
Female 5 4 
0.68 
Male 9 10 
Age (years) 41.79±2.72 41.86±3.32 0.98 
Body mass index(kg/m²) 21.93±1.28 22.76 ± 1.41 0.60 
Comorbities (n)#    
Hypertension 10 6 
0.15 
Diabetes 1 1 
Hypertension + Diabetes 0 1 
Glomerulonephritis 2 0 
Others 1 3 
Unknown 0 3 
 
#Chi-square.  400 
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Energy (kcal) 1629.57±265.52 1553.46±157.42 0.80 
Carbohydrate (g) 180.35±26.93 177.91±21.54 0.94 
Total fat (g) 66.90±12.21 64.67±6.64 0.57 
Monounsaturated fat (g) 18.64±2.35 18.30±2.30 0.80 
Polyunsaturated fat (g) 15.81±2.21 15.21±1.81 1.00 
Saturated fat (g) 16.16±2.25 16.17±2.26 0.98 
Cholesterol (mg) 255.75±74.67 272.12±36.83 0.21 
Protein (g) 76.47±14.27 65.96±8.17 0.63 
Protein (g/kg b.w.) 1.31±0.23 1.14±0.16 0.54 
Calcium (mg) 352.75±90.62 367.63±65.16 0.37 
Iron (mg) 8.26±1.15 6.85±0.70 0.35 
Phosphorus (mg) 948.06±184.36 825.70±80.32 1.00 
Magnesium (mg) 177.82±22.17 168.30±20.57 0.70 
Potassium (mg) 1880.31±254.44 1847.39±257.60 0.98 
Sodium (mg) 3860.10±644.30 3551.40±381.10 0.66 
Dietary fiber (g) 16.75±1.96 14.52±1.78 0.35 
Mann-Whitney test; b.w.: body weight. 402 
69 
 
   
Table 4. Comparison of MIS, body composition and biochemical parameters among the groups. 
MIS: malnutrition inflammatory score.  
* p<0.05 was considered as significant;#difference vs pre; a≠b difference in two-way ANOVA followed of post hoc Tukey test.
Variables 
Placebo (n=14) 
Mean ± SEM 
Creatine (n=14) 
Mean ± SEM 
  





MIS 5.71±0.97a 5.36±0.95 a -0.36±0.39 5.57±0.72 a 3.85±0.47 b# -1.71±0.37 0.01* 0.964 0.01* 
Body composition           
Body weight (kg) 58.91±3.67 59.42±3.69# 0.51±0.21 62.07±4.83 62.84±4.81# 0.77±0.24 0.43 0.301 0.43 
Body mass index(kg/m²) 21.93±1.28 22.13±1.30 0.19±0.09 22.76±1.41 23.04±1.39# 0.27±0.08 0.52 0.245 0.33 
Arm circumference (cm) 27.68±1.16 27.81±1.13 0.12±0.23 28.59±1.60 28.38±1.35 -0.20±0.71 0.65 0.160 0.66 
Thigh circumference(cm) 45.46±1.86 45.30±1.76 -0.15±0.58 45.61±1.94 45.96±1.93 0.35±0.14 0.41 0.312 0.41 
Calf circumference(cm) 33.51±1.17 32.55±0.82 -0.96±0.74 33.77±1.42 34.04±1.40 0.27±0.16 0.11 0.608 0.11 
Gait speed (m/s) 0.81±0.03 0.78±0.03 -0.03±0.04 0.72±0.03 0.78±0.03# 0.05±0.02 0.09 0.647 0.22 
Lean body mass (kg) 41.33±2.28 a 41.46±2.36 a 0.13±0.21 42.96±2.74b 43.92±2.71a# 0.95±0.30 0.03* 0.832 0.03* 
Fat body mass (kg) 15.23±2.51 a 15.63±2.52b # 0.39±0.12 16.77±2.93 b 16.60±2.95 b -0.17±0.01 0.02* 0.903 0.02* 
Biochemical parameters          
Creatinine (mg/dL) 5.86±0.60 a 5.03±0.45 a -0.82±1.94 4.04±0.49 b 5.95±0.84 a# 1.90±0.76 0.00* 1.113 0.00* 
Urea pre (mg/dL) 136.92±8.05 150.42±11.89 13.50±8.41 133.42±10.76 131.92±8.22 -1.50±7.77 0.20 0.495 0.20 
Urea post (mg/dL) 36.79±6.55 30.07±6.76 -6.71±4.21 40.71±7.38 44.86±5.64 4.14±8.16 0.24 0.446 0.24 
Phosphorus (mg/dL) 5.32±0.65 5.50±0.89 0.17±0.40 5.71±0.44 5.72±0.46 0.01±0.32 0.76 0.115 0.76 
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Mean ± SEM 
Creatine (n=14) 
Mean ± SEM 
  





Physical function 75.00±6.54 67.50±13.60 -7.50±16.52 71.78±10.19 75.71±10.34 3.92±2.46 0.94 0.258 0.49 
Role limitation physical 42.85±9.95 44.64±19.98 1.78±22.76 42.85±13.97 51.78±14.70 8.92±9.66 0.66 0.109 0.77 
Pain 55.35±7.39 57.71±10.40 2.35±12.59 62.14±8.90 65.57±8.03 3.42±7.9 0.83 0.027 0.94 
General health 49.35±5.15 43.57±8.73 -5.78±11.54 38.71±7.19 40.14±6.14 1.42±4.67 0.91 0.219 0.56 
Vitality 53.57±4.23 51.78±8.36 -1.78±9.64 54.28±6.54 60.35±6.51 6.07±3.32 0.73 0.291 0.44 
Social function 70.53±5.94 70.53±11.83 0.00±13.55 82.14±7.14 90.17±5.10 8.03±5.17 0.83 0.209 0.58 
Emotional function 59.52±12.19 47.61±19.67 -11.90±20.25 47.61±16.65 64.27±15.80 16.66±13.87 0.35 0.439 0.25 
Mental health 65.71±6.04 62.28±10.48 -3.42±10.47 69.71±6.47 71.71±4.65 2.00±5.19 0.66 0.175 0.64 
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Supplementary Figure 1. Participant flowchart (CONSORT). 
 
